111 Capital’s Charles River Laboratories CRL Stock Holding History

111 Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,447	Closed	-$226K	–	371
2025 Q3	$226K	Buy	+1,447	New	+$230K	0.04%	391

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

111 Capital's CRL Position: Q4 2025 in Review

111 Capital sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 1,447 shares — an estimated $226K sold.

111 Capital first reported a position in CRL in Q3 2025 and held it in 1 quarter. The position peaked at $226K in Q3 2025. 583 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

111 Capital reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
111 Capital sold 1,447 Charles River Laboratories shares in Q4 2025, an estimated $226K.
111 Capital first reported a position in Charles River Laboratories in Q3 2025 and held it in 1 quarter.
111 Capital's Charles River Laboratories position peaked at $226K in Q3 2025.
583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on 111 Capital's 13F filing for Q4 2025, filed 11 Feb 2026.